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PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS

or a pharmaceutically acceptable salt thereof wherein R 1 is
---C 1 _4 alky, optionally substituted with hydroxy.
Specifically, a compound of formula I wherein R 1 is
methyl.
Specifically, a compound of formula I wherein R 1 is ethyl
or cyclobutyl.
In another aspect, the present invention also provides:
pharmaceutical compositions which comprise a pharmaceutically acceptable carrier and a compound of formula I,
methods for controlling or treating a disorder or condition
selected from organ transplant rejections, lupus, multiple
sclerosis, rheumatoid arthritis, psoriasis, cancer, osteoarthritis, and diabetes by administering to a mammal in need a
therapeutically effective amount of a compound of formula I
or a pharmaceutically acceptable salt thereof,
methods for controlling or treating a disorder or condition
selected from diabetes, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, dry eyes, Alzheimer's disease, leukemia, and other indications where immunosuppression or immunomodulation would be desirable by
administering to a mammal in need a therapeutically effective
amount of a compound of formula I or a pharmaceutically
acceptable salt thereof,
methods for controlling or treating a disorder or condition
selected from allergic reaction including allergic dermatitis,
eczema, atopic dermatitis, pruritus and other pruritic conditions and inflammatory disease such as bowel disease in
mammal by administering to a mammal in need a therapeutically effective amount of a compound of formula I or a
pharmaceutically acceptable salt thereof,
methods for controlling or treating a disorder or condition
selected from Asthma and other obstructive airways diseases,
including chronic or inveterate asthma, late asthma, airway
hyper-responsiveness, bronchitis, bronchial asthma, allergic
asthma, intrinsic asthma, extrinsic asthma, dust asthma,
recurrent airway obstruction, and chronic obstruction pulmonary disease by administering to a mammal in need a therapeutically effective amount of a compound of formula I or a
pharmaceutically acceptable salt thereof,
methods for the inhibition of protein tyrosine kinases or
JAK-1, JAK-2, JAK-3 and/or Tyk-2 by administering to a
mammal in need of a therapeutically effective amount of a
compound of formula I or a pharmaceutically acceptable salt
thereof,
methods for the inhibition of protein tyrosine kinases or
JAK-1, JAK-2, JAK-3 and/or Tyk-2 by administering to a
mammal in need of a therapeutically effective amount of a
compound of formula I or a pharmaceutically acceptable salt
thereof, and methods for the preparation of compounds of the
present invention.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a divisional of U.S. patent application
Ser. No. 12/542,451 filedAug. 17, 2009, now allowed, which
claims the benefit of priority to U.S. Provisional Application
No. 61/090,371 filed Aug. 20, 2008, now abandoned.
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FIELD OF THE INVENTION

10

Described herein is N-methyl( 4-(methyl(7H-pyrrolo[2,3d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide,
its analogues, their use as Janus Kinase (JAK) inhibitors,
pharmaceutical compositions containing these compounds,
and methods for the preparation of these compound.

15

BACKGROUND OF THE INVENTION
Protein kinases are families of enzymes that catalyze the
phosphorylation of specific residues in proteins, broadly classified into tyrosine and serine/threonine kinases. Inappropriate kinase activity, arising from mutation, over-expression, or
inappropriate regulation, dys-regulation or de-regulation, as
well as over- or under-production of growth factors or cytokines has been implicated in many diseases, including but not
limited to cancer, cardiovascular diseases, allergies, asthma
and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic disorders, and neurological and neurodegenerative disorders such as Alzheimer's disease. Inappropriate kinase activity triggers a variety
of biological cellular responses relating to cell growth, cell
differentiation, survival, apoptosis, mitogenesis, cell cycle
control, and cell mobility implicated in the aforementioned
and related diseases.
Thus, protein kinases have emerged as an important class
of enzymes as targets for therapeutic intervention. In particular, the JAK family of cellular protein tyrosine kinases (JAK1, JAK-2, JAK-3, and Tyk-2) play a central role in cytokine
signaling (Kisseleva et al, Gene, 2002, 285, 1; Yamaoka et al.
Genome Biology 2004, 5, 253)). Upon binding to their receptors, cytokines activate JAK which then phosphorylate the
cytokine receptor, thereby creating docking sites for signaling molecules, notably, members of the signal transducer and
activator of transcription (STAT) family that ultimately lead
to gene expression. Numerous cytokines are known to activate the JAK family.
Accordingly, there remains a need for alternative compounds that effectively inhibit JAK enzymes, including JAK1, JAK-2, JAK-3, and/or Tyk-2.
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SUMMARY OF THE INVENTION
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BRIEF DESCRIPTION OF THE DRAWINGS

The present invention provides a compound of formula I:

H

\

55

S/N-RI

//~
'-....

0

N
60

l_jLN)

FIG. 1 is a characteristic X-ray powder diffraction pattern
of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino ]cyclohexyl}methanesulfonamide
maleic
acid salt (Form A).
FIG. 2 illustrates Day 27VAS Scores for Example 1bin flea
allergic dogs in the Reducing Flea-associated Pruritus and
Dermatitis Assay
FIG. 3 illustrates Seconds of Pruritus per 4 hour recording
for example 1b in flea allergic dogs in the Reducing Fleaassociated Pruritus and Dermatitis Assay.
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With respect to the above compound, and throughout the
application and claims, the following terms have the meanings defined below.

US 8,987,283 B2
4

3
The term "mammal" refers to human or animals including
livestock and companion animals. The phrase "companion
animal" or "companion animals" refers to animals kept as
pets. Examples of companion animals include cats, dogs, and
horses. The term "livestock" refers to animals reared or raised
in an agricultural setting to make products such as food or
fiber, or for its labor. In some embodiments, livestock are
suitable for consumption by marmnals, for example humans.
Examples of livestock animals include mammals, such as
cattle, goats, horses, pigs, sheep, including lambs, and rabbits, as well as birds, such as chickens, ducks and turkeys.
The term "controlling", "treating" or "treatment" of a disease includes: (1) preventing the disease, i.e. causing the
clinical symptoms or signs of the disease not to develop in a
mammal that may be exposed to or predisposed to the disease
but does not yet experience or display symptoms/signs of the
disease; (2) inhibiting the disease, i.e., arresting or reducing
the development of the disease or its clinical symptoms/signs;
or (3) relieving the disease, i.e., causing regression of the
disease or its clinical symptoms/signs.
The term "therapeutically effective amount" means the
amount of a compound that, when administered to a mammal
for treating a disease, is sufficient to effect such treatment for
the disease. The "therapeutically effective amount" will vary
depending on the compound, the disease and its severity and
the age, weight, etc., of the mammal to be treated.
The term "approximately" if used in defining a peak in an
X-ray powder diffraction pattern is defined as the stated
2-theta value±0.2 degree 2-theta. Any determination of
whether a crystalline form is the Form A polymorph and
encompassed by the claims should be interpreted in light of
the variability in this test.
"Pharmaceutically acceptable" means suitable for use in
mammals, companion animals or livestock animals.
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum
and maximum number of carbon atoms in the moiety, i.e., the
prefix C,_1 indicates a moiety of the integer "i" to the integer
"j" carbon atoms, inclusive. Thus, for example, C 1 _4 alkyl
refers to alkyl of one to four carbon atoms, inclusive.
The term alkyl refers to straight, branched and a cyclic
saturated monovalent hydrocarbon groups, but reference to
an individual radical such as "propyl" embraces only the
straight chain radical, a branched chain isomer such as "isopropyl" or a cyclic isomer such as cyclopropylmethyl or
cyclopentyl being specifically referred to.
Compounds that have the same molecular formula but
differ in the nature or sequence of bonding of their atoms or
the arrangement of their atoms in space are termed "isomers".
Isomers that differ in the arrangement of their atoms in space
are termed "stereoisomers". It will be appreciated by those
skilled in the art that the compound of formula I can exist as
cis- and trans-achiral diastereomers. Specifically, the present
invention provides a compound of formula IA, which has the
chemical name N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,
3-d]pyrimidin-4-yl)amino]
cyclohexy1} methanesulfonamide,

IA
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or a pharmaceutically acceptable salt thereof.
Included within the scope of the described compounds are
all isomers (e.g. cis-, trans-, or diastereomers) of the compounds described herein alone as well as any mixtures. All of
these forms, including enantiomers, diastereomers, cis, trans,
syn, anti, solvates (including hydrates), tautomers, and mixtures thereof, are included in the described compounds.
Stereoisomeric mixtures, e.g. mixtures of diastereomers,
can be separated into their corresponding isomers in a known
manner by means of suitable separation methods. Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar
procedures. This separation may take place either at the level
of one of the starting compounds or in a compound of formula
I itself. Enantiomers may be separated through the formation
of diastereomeric salts, for example by salt formation with an
enantiomer-pure chiral acid, or by means of chromatography,
for example by HPLC, using chromatographic substrates
with chiral ligands.
Routes of Administration
In therapeutic use for treating disorders in a mammal (i.e.
human and animals), a compound of the present invention or
its pharmaceutical compositions can be administered orally,
parenterally, topically, rectally, transmucosally, or intestinally. Parenteral administrations include indirect injections to
generate a systemic effect or direct injections to the afflicted
area. Topical administrations include the treatment of skin or
organs readily accessibly by local application, for example,
eyes or ears. It also includes transdermal delivery to generate
a systemic effect. The rectal administration includes the form
of suppositories. The preferred routes of administration are
oral and parenteral.
Pharmaceutical Salts
The compound of formula I may be used in its native form
or as a salt. In cases where forming a stable nontoxic acid or
base salt is desired, administration of the compound as a
pharmaceutically acceptable salt may be appropriate. Pharmaceutically acceptable salts of the compounds of formula I
include the acetate, ascorbate, aspartate, benzoate, besylate,
bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, etoglutarate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, glycerophosphate,
hexafluorophosphate, hibenzate, hydrochloride/chloride,
hydro bromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate,
naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate,
palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.
Composition/Formulation
Pharmaceutical compositions of the present invention may
be manufactured by processes well known in the art, e.g., by
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means of conventional mixing, dissolving, granulation, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.
Pharmaceutical compositions for use in accordance with
the present invention may be formulated in conventional
manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate
processing of the active compound into preparations, which
can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Pharmaceutically acceptable excipients and carriers are generally known
to those skilled in the art and are thus included in the instant
invention. Such excipients and carriers are described, for
example, in "Remingtons Pharmaceutical Sciences" Mack
Pub. Co., New Jersey (1991).
The formulations of the invention can be designed to be
short-acting, fast-releasing, long-acting, and sustained-releasing. Thus, the pharmaceutical formulations can also be
formulated for controlled release or for slow release.
Dosage
Pharmaceutical compositions suitable for use in the
present invention include compositions wherein the active
ingredients are contained in an amount sufficient to achieve
the intended purpose, i.e., control or the treatment of disorders or diseases. More specifically, a therapeutically effective
amount means an amount of compound effective to prevent,
alleviate or ameliorate symptoms/signs of disease or prolong
the survival of the subject being treated.
The quantity of active component, which is the compound
of this invention, in the pharmaceutical composition and unit
dosage form thereof, may be varied or adjusted widely
depending upon the manner of administration, the potency of
the particular compound and the desired concentration.
Determination of a therapeutically effective amount is well
within the capability of those skilled in the art. Generally, the
quantity of active component will range between 0.01 % to
99% by weight of the composition.
Generally, a therapeutically effective amount of dosage of
active component will be in the range of about 0.01 to about
100 mg/kg of body weight/day, preferably about 0.1 to about
10 mg/kg of body weight/day, more preferably about 0.3 to 3
mg/kg of body weight/day, even more preferably about 0.3 to
1.5 mg/kg of body weight/day It is to be understood that the
dosages may vary depending upon the requirements of each
subject and the severity of the disorders or diseases being
treated.
The desired dose may conveniently be presented in a single
dose or as divided doses administered at appropriate intervals,
for example, as two, three, four or more sub-doses per day.
The sub-dose itself may be further divided, e.g., into a number
of discrete loosely spaced administrations; such as multiple
inhalations from an insufflator or by application of a plurality
of drops into the eye.
Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in
order to rapidly achieve the desired plasma concentration. On
the other hand, the initial dosage may be smaller than the
optimum and the daily dosage may be progressively
increased during the course of treatment depending on the
particular situation. If desired, the daily dose may also be
divided into multiple doses for administration, e.g., two to
four times per day.
Medical and Veterinary Uses
Compounds of the present invention are Janus Kinase
inhibitors (JAK-i) with efficacy against Janus Kinase- I (JAK1), Janus Kinase-2 (JAK-2) and Janus Kinase-3 (JAK-3).
Accordingly, they are useful as therapeutic agents for organ

transplants, lupus, multiple sclerosis, rheumatoid arthritis,
psoriasis, Type I diabetes and complications from diabetes,
cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn' s disease, Alzheimer's disease,
leukemia, osteoarthritis, control of pruritus, chronic respiratory disease and other indications where immunosuppression/immunomodulation would be desirable.
In addition, there are substantial needs for safe and efficacious agents to control atopic dermatitis in animals. The market for treating atopic dermatitis in animals is currently dominated by corticosteroids, which cause distressing and
undesirable side effects in animals, specifically in companion
animals such as dogs. Antihistamines are also used, but are
poorly effective. A canine formulation of cyclosporine
(ATOPICA™) is currently being marketed for atopic dermatitis, but is expensive and has a slow onset of efficacy. In
addition, there are GI toleration issues with ATOPICA™.
Compounds of present invention are JAK inhibitors with
efficacy against JAK-1 and JAK-3. These compounds will be
an alternative to steroid usage and provide resolution of
chronic pruritus and inflammation that would either persist in
atopic dermatitis or slowly regress following removal of allergen or causative agent, such as fleas in flea-allergic dermatitis.
Compounds of the present invention may be administered
in a pharmaceutically acceptable form either alone or in combination with one or more additional agents which modulate
a mammalian immune system or with antiinflammatory
agents. These agents may include but are not limited to
cyclosporin A (e.g. Sandimmune® or Neoral®, rapamycin,
FK-506 (tacrolimus), leflunomide, deoxyspergualin, mycophenolate (e.g. Cellcept®, azathioprine (e.g. Imuran®),
daclizumab (e.g. Zenapax®), OKT3 (e.g. Orthocolone®),
AtGam, aspirin, acetaminophen, ibuprofen, naproxen,
piroxicam, and antiinflanimatory steroids (e.g. prednisolone
or dexamethasone). These agents may be administered as part
of the same or separate dosage forms, via the same or different
routes of administration, and on the same or different administration schedules according to standard pharmaceutical
practice known to one skilled in the art.
In one embodiment, the invention provides methods of
treating or preventing a disease, condition or disorder associated with JAK in a subject, such as a human or non-human
mammal, comprising administering an effective amount of
one or more compounds described herein to the subject. The
JAK associated disease, condition or disorder can be related
to JAK-1, JAK-2, JAK-3, and/orTyk-2. Suitable subjects that
can be treated include domestic or wild animals, companion
animals, such as dogs, cats, horses and the like; livestock
including, cows and other ruminants, pigs, poultry, rabbits
and the like; primates, for example monkeys, such as rhesus
monkeys and cynomolgus (also known as crab-eating or
long-tailed) monkeys, marmosets, tamarins, chimpanzees,
macaques and the like; and rodents, such as rats, mice, gerbils, guinea pigs and the like. In one embodiment, the compound is administered in a pharmaceutically acceptable form,
optionally in a pharmaceutically acceptable carrier.
JAK/STAT signaling has been implicated in the mediation
of many abnormal immune responses such as allergies,
asthma, autoimmune diseases such as transplant (allograft)
rejection, rheumatoid arthritis, amyotrophic lateral sclerosis
and multiple sclerosis, as well as in solid and hematologic
malignancies such as leukemia and lymphomas. For a review
of the pharmaceutical intervention of the JAK/STAT pathway
see Frank, (1999), Mo!. Med. 5:432:456 and Seidel et al.,
(2000), Oncogene 19:2645-2656.
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JAK-3 in particular has been implicated in a variety of
biological processes. For example, the proliferation and survival of murine mast cells induced by IL-4 and IL-9 have been
shown to be dependent on JAK-3 and gamma chain-signaling. Suzuki et al., (2000), Blood 96:2172-2180. JAK-3 also
plays a crucial role in IgE receptor-mediated mast cell
degranulation responses (Malaviya et al., (1999), Biochem.
Biophys. Res. Commun 257:807-813), and inhibition of
JAK-3 kinase has been shown to prevent type I hypersensitivity reactions, including anaphylaxis (Malaviya et al.,
(1999), J. Biol. Chem. 274:27028-27038). JAK-3 inhibition
has also been shown to result in immune suppression for
allograft rejection (Kirken, (2001), Transpl. Proc. 33:32683270). JAK-3 kinaseshavealso been implicated in the mechanism involved in early and late stages of rheumatoid arthritis
(Muller-Ladner et al., (2000), J. Immunal. 164:3894-3901);
familial amyotrophic lateral sclerosis (Trieu et al., (2000),
Biochem Biophys. Res. Commun. 267:22-25); leukemia
(Sudbeck et al., (1999), Clin. Cancer Res. 5:1569-1582);
mycosis fungoides, a form ofT-cell lymphoma (Nielsen et al.,
(1997), Prac. Natl. Acad. Sci. USA 94:6764-6769); and
abnormal cell growth (Yu et al., (1997), J. Immunol. 159:
5206-5210; Catlett-Falcone et al., (1999), Immunity 10: 105115).
The JAK kinases, including JAK-3, are abundantly
expressed in primary leukemic cells from children with acute
lymphoblastic leukemia, the most common form of childhood cancer, and studies have correlated STAT activation in
certain cells with signals regulating apoptosis (Demoulin et
al., (1996), Mo!. Cell. Biol. 16:4710-6; Jurlander et al.,
(1997), Blood 89:4146-52; Kaneko et al., (1997), Clin. Exp.
Immun 109:185-193; and Nakamura et al., (1996), J. Biol.
Chem. 271: 19483-8). They are also known to be important to
lymphocyte differentiation, function and survival. JAK-3 in
particular plays an essential role in the function of lymphocytes, macrophages, and mast cells. Given the importance of
this JAK kinase, compounds which modulate the JAK pathway, including those selective for JAK-3, can be useful for
treating diseases or conditions where the function oflymphocytes, macrophages, or mast cells is involved (Kudlacz et al.,
(2004)Am. J. Transplant4:51-57; Changelian (2003) Science
302:875-878).
Conditions in which targeting of the JAK pathway or
modulation of the JAK kinases, particularly JAK-3, are contemplated to be therapeutically useful include, arthritis,
asthma, autoimmune diseases, cancers or tumors, diabetes,
certain eye diseases, disorders or conditions, inflammation,
intestinal inflammations, allergies or conditions, neurodegenerative diseases, psoriasis, transplant rejection, and viral
infection. Conditions which can benefit for inhibition of
JAK-3 are discussed in greater detail below.
Accordingly, the compound of formula I or its pharmaceutically acceptable salts and pharmaceutical compositions can
be used to treat a variety of conditions or diseases such as:
Arthritis, including rheumatoid arthritis, juvenile arthritis,
and psoriatic arthritis;
Asthma and other obstructive airways diseases, including
chronic or inveterate asthma, late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma, allergic asthma,
intrinsic asthma, extrinsic asthma, dust asthma, recurrent airway obstruction, and chronic obstruction pulmonary disease;
Autoimmune diseases or disorders, including those designated as single organ or single cell-type autoimmune disorders, for example Hashimoto's thyroiditis, autoimmune
hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune
orchitis, Goodpasture's disease, autoimmune thrombocy-

topenia, sympathetic ophthalmia, myasthenia gravis, Graves'
disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy, those
designated as involving systemic autoimmune disorder, for
example systemic lupus erythematosis, rheumatoid arthritis,
Sjogren's syndrome, Reiter's syndrome, polymyositis-dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis and bullous pemphigoid, and additional
autoimmune diseases, which can be O-cell (humoral) based
or T-cell based, including Cogan's syndrome, ankylosing
spondylitis, Wegener's granulomatosis, autoimmune alopecia, Type I or juvenile onset diabetes, and thyroiditis;
Cancers or tumors, including alimentary/gastrointestinal
tract cancer, colon cancer, liver cancer, skin cancer including
mast cell tumor and squamous cell carcinoma, breast and
mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, including acute myelogenous leukemia
and chronic myelogenous leukemia, kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer, brain cancer,
melanoma including oral and metastatic melanoma, Kaposi's
sarcoma, myelomas including multiple myeloma, myeloproliferative disorders, proliferative diabetic retinopathy, and
angiogenic-associated disorders including solid tumors;
Diabetes, including Type I diabetes and complications
from diabetes;
Eye diseases, disorders or conditions including autoimmune diseases of the eye, keratoconjunctivitis, vernal conjunctivitis, uveitis including uveitis associated with Behcet's
disease and lens-induced uveitis, keratitis, herpetic keratitis,
conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular premphigus, Mooren's ulcer, scleritis, Grave's
ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, sympathetic ophthalmitis, allergic conjunctivitis, and ocular neovascularization;
Intestinal inflammations, allergies or conditions including
Crohn' s disease and/or ulcerative colitis, inflammatory bowel
disease, coeliac diseases, proctitis, eosinophilic gastroenteritis, and mastocytosis;
Neurodegenerative diseases including motor neuron disease, Alzheimer's disease, Parkinson's disease, amyotrophic
lateral sclerosis, Huntington's disease, cerebral ischemia, or
neurodegenerative disease caused by traumatic injury, strike,
glutamate neurotoxicity or hypoxia; ischemic/reperfusion
injury in stroke, myocardial ischemica, renal ischemia, heart
attacks, cardiac hypertrophy, atherosclerosis and arteriosclerosis, organ hypoxia, and platelet aggregation;
Skin diseases, conditions or disorders including atopic dermatitis, eczema, psoriasis, scleroderma, pruritus and other
pruritic conditions;
Allergic reactions including allergic dermatitis in mammal
including horse allergic diseases such as bite hypersensitivity,
sUllliller eczema and sweet itch in horses.
Transplant rejection, including pancreas islet transplant
rejection, bone marrow transplant rejection, graft-versus-host
disease, organ and cell transplant rejection such as bone marrow, cartilage, cornea, heart, intervertebral disc, islet, kidney,
limb, liver, lung, muscle, myoblast, nerve, pancreas, skin,
small intestine, or trachea, and xeno transplantation; and
Another embodiment provides a method of inhibiting a
JAK enzyme, including JAK-1, JAK-2, JAK-3 and/orTyk-2,
that includes contacting the JAK enzyme with either a nontherapeutic amount or a therapeutically effective amount of
one or more of the present compounds. Such methods can
occur in vivo or in vitro. In vitro contact can involve a screening assay to determine the efficacy of the one or more compounds against a selected enzyme at various amounts or con-
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centrations. In vivo contact with a therapeutically effective
amount of the one or more compounds can involve treatment
of a described disease, disorderor condition or prophylaxis of
organ transplant rejection in the animal in which the contact
occurs. The effect of the one or more compounds on the JAK
enzyme and/or host animal can also be determined or measured. Methods for determining JAK activity include those
described in the Examples as well as those disclosed in WO
99/65908, WO 99/65909, WO 01/42246, WO 02/00661, WO
02/096909, WO 2004/046112 or WO 2007/012953.
The following reaction schemes illustrate the general synthetic procedures of the compounds of the present invention.
All starting materials are prepared by procedures described in
these schemes or by procedures known to one of ordinary
skill in the art.

This may be achieved by conventional methods, for example
as described in "Protective Groups in Organic Synthesis" by
T W Greene and PG M Wuts, John Wiley & Sons Inc (1999),
and references therein.
In Scheme I, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (a)
can be obtained commercially. trans-4-(Methylamino )-cyclohexyl]methanol (b) may be obtained from the corresponding carboxylic acid, trans-4-[ (tert-butoxycarbony1)amino ]cyclohexanecarboxy lic acid, upon treatment with a reducing
agent such as lithium aluminium hydride in an aprotic, anhydrous solvent such as tetrahydrofuran at temperatures
between 0-60° C. for several hours.
As shown in Scheme I, a compound of structure (c) can be
synthesized by the reaction of 4-chloro-7H-pyrrolo[2,3-d]
pyrimidine (a) with trans-4-(methylamino )-cyclohexyl]
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It will be apparent to those skilled in the art that sensitive
functional groups (Pg or Pgl) may need to be protected and
deprotected during synthesis of a compound of the invention.
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methanol (b) in a suitable aprotic, polar solvent such as N,Ndimethylformamide,
aqueous
dioxane
and
dimethylsulfoxide, in the presence of a suitable base such as
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triethylamine and potassium carbonate at elevated temperabe employed in a polar solvent such as acetic acid, if the
tures up to 90° C. for up to a few hours.
reaction is performed in the presence of potassium acetate the
A compound of structure (d) could be synthesized in a two
potassium salt of the compound of formula (g) is produced.
step procedure from a compound of structure (c). For
It is envisaged that a compound of structure (g) may be
example, a compound of structure (d) would be synthesized 5
synthesized directly from a compound of structure (e) upon
by firstly using brominating reagents such as thionyl bromide
treatment with a suitable sulfur nucleophile such as sodium
or phosphorous tribromide in a polar, aprotic solvent such as
sulfite in a polar solvent. Similarly, a compound of structure
methylene chloride to afford the unprotected cyclohexylm(g) could be synthesized from a compound of structure (d)
ethylbromide, and secondly by addition of a suitable protect10 upon nucleophilic substitution with sodium sulfite.
ing reagent such as tosyl chloride to give the protected comTreatment of sulphonic acids of formula (g) with a chloripound of structure (d).
nating
agent such as thionyl chloride in an aprotic, polar
A compound of structure (e) can be prepared by using
solvent
such as methylene chloride with a polar cosolvent
simple protection processes from a compound of structure
(c). For example, when Pg and Pg 1 are both tosyl, this can be 15 such as N,N-dimethylformamide at reflux gives the chlorinated compounds. The chlorinated compound then reacts in
effected in a one step reaction upon treatment of the unproan aprotic, anhydrous solvent such as tetrahydrofuran with
tected compound of structure (c) with tosyl chloride in the
suitable amines in neat, gaseous form, or dissolved in an
presence of a polar, aprotic solvent such as methylene chloaprotic, anhydrous solvents such as tetrahydrofuran, at room
ride, a catalyst such as DMAP and a weak base such as
20
temperature to produce a compound of structure (h). Optiontriethy!amine.
ally an anhydrous, weak base such as triethylamine may be
A compound of structure (f) may be synthesized from a
compound of structure (e) by
used to mop up hydrochloric acid generated in the reaction.
S-alkylation using a suitable nucleophile. Thus compounds
Compounds of formula I of the present invention may be
of structure (e) wherein the protecting group (PO is a suitable 25 prepared from compounds of formula (h) wherein Pg is a
hydroxyl protecting group such as tosyl or mesyl may be
suitable protecting group by deprotection procedures known
reacted with potassium thioacetate in a polar solvent such as
to one skilled in the art. For example, when the protecting
dimethylsulfoxide or N-methylpyrrolidine at elevated temgroup (Pg) is tosyl, suitable deprotection conditions involve
peratures up to 7 5° C. for up to 2 hours to give compounds of
reaction with a base such as lithium hydroxide or potassium
30
structure (f).
hydroxide in a protic solvent such as methanol or isopropanol
A compound of structure (g) may be synthesized by an
and optionally miscible cosolvents such as tetrahydrofuran
oxidation procedure from compounds of formula (f). Many
and water at room temperature for several hours, to produce
oxidizing conditions are known to those skilled in the art, for
the deprotected amine of formula I.
example those described in "Handbook of Reagents for 35
Salts of compounds of formula I may be formed by the
Organic Synthesis-Oxidising and Reducing Agents" edited
reaction of the free base of compounds of formula I with a
by S. D. Burke and R. L. Danheiser. For example, a compound
suitable acid such as maleic acid in the presence of a protic
of structure (f), optionally wetted with water, can be treated
solvent such as butanol and optionally a cosolvent such as
with formic acid followed by slow addition of hydrogen perwater.
oxide whilst stirring at room temperature for about 15 hours 40
Alternatively, compounds of this invention can be prepared
to give a compound of structure (g). Alternatively, oxone may
in accordance with Scheme II.
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In Scheme II, 4-methy1-7 -[ (4-methy!phenyl )sulfony I]-7H-

drous, weak base such as triethylamine may be used to mop
up hydrochloric acid generated in the reaction.

pyrrolo [2,3-d]pyrimidine (j) can be obtained from commercially available (a) using a protecting agent such as tosyl

20

chloride using procedures well known in the art. trans-4(Methylamino )-cyclohexyl]methanol (b) may be obtained
from the corresponding carboxylic acid, trans-4-[(tert-butoxycarbonyl)amino ]cyclohexanecarboxylic

acid,

upon

25

EXAMPLES
Preparation 1 N-Methyl-l-[trans-4-(methyl {7-[(4methy lpheny I)sulfony I]-7H-pyrrolo [2,3-d]pyrimidin4-y l }amino )cyclohexyl]methanesulfonamide

treatment with a reducing agent such as Vitride in an anhydrous solvent such as toluene at temperatures between 0-110°
C. for several hours.
As shown in Scheme II, a compound of structure (k) can be
synthesized by the reaction of 4-chloro-7H-pyrrolo[2,3-d]
pyrimidine (j) with trans-4-(methylamino )-cyclohexyl]
methanol (b) in a suitable solvent such as acetone, in the
presence of a suitable base such as triethylamine with a catalytic amount of potassium iodide at elevated temperatures up
to 60° C. for up to a few hours.
A compound of structure (k) could synthesized by addition
of a suitable mesylating reagent such as mesyl chloride in the
presence of a suitable base such as triethylamine or diethylisopropylamine in a suitable solvent such as acetone at
elevated temperatures up to 60° C. to give the methane sulfonyl compound of structure (k).
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A compound of structure (I) can be prepared by using
simple S-alkylation processes from a compound of structure
(k) using a suitable nucleophile. Thus compounds of structure
(k) may be reacted with sodium sulphite in solvent such as

50

isopropylalcohol or water or toluene at elevated temperatures
up to 90° C. for up to 4 hours to give compounds of structure
(1 ).
Treatment of sulphonic acids of formula (I) with a chlori-

55

nating agent such as thionyl chloride in an aprotic, polar
solvent such as THF or methylene chloride with a polar
cosolvent such as N,N-dimethylformamide at temperatures
between O and 40° C. gives the chlorinated compounds. The
chlorinated compound then reacts in an aprotic, anhydrous
solvent such as tetrahydrofuran with suitable amines such as
methyl amine, cyclobutyl amine or 2-hydroxyazetidine preferably in neat, gaseous form, or dissolved in an aprotic, anhydrous solvents such as tetrahydrofuran, at room temperature
to produce a compound of structure (h). Optionally an anhy-
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Method (a) To a solution of the compound of Preparation 2
(308.0 gwetweight, 214.5 g dry weight, 0.41 mo!) in tetrahydrofuran (1.0 I) is added methylamine (2M in tetrahydrofuran, 687 ml) over 1 h. After stirring at room temperature for 30
min, additional methylamine (2M in tetrahydrofuran, 53 ml)
is added and the reaction mixture is stirred at room temperature for 18 h. The mixture is reduced in volume to 600 ml, via
vacuum distillation, and tetrahydrofuran (300 ml) is added,
before the mixture is again reduced in volume to approximately 750 ml. To the mixture, heated at 45° C., is added
2-propanol (247 ml) and water (693 ml). After cooling to
room temperature, the solid material is collected by filtration,
washed with water (2x250 ml) and dried in vacuo at 65° C. to
give the title compound (180.4 g).
1
H-NMR (d 6 -DMSO): 1.17-1.32 (2H), 1.57-1.73 (4H),
1.76-1.92 (lH), 1.93-2.08 (2H), 2.30-2.39 (3H), 2.53-2.62
(3H), 2.87-2.98 (2H), 3.07-3.17 (3H), 4.53-4.75 (lH), 6.816.94 (lH), 7.38-7.47 (2H), 7.56-7.65 (lH), 7.92-8.02 (2H),
8.15-8.27 (lH).
Method (b) To a solution of the compound of Preparation 2
(165 g, 0.34 mo!) in THF (1.65 I) and N,N-dimethylforma-
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mide (5.0 ml) at 0-5° C. is added thionyl chloride (125 ml, 17
mo!), over 25 min. The reaction mixture was stirred for 30
minutes at 0-5° C. then slowly heated to 40° C. for 8 h. After
cooling to r.t. the solvent was evaporated under reduced pressure and azeotroped with THF to removed thionyl chloride.
To the sulphonyl chloride obtained was added fresh THF
(1.65 I) and the mixture cooled to 0° C. Dry N-methylamine
gas was purged for 30 minutes and the reaction stirred for a
further 4 hours at r.t. The solvent was evaporated to half of its
volume (800 ml) and heptane (1.5 I) added. The product
precipitated out and was filtered and washed with water (1 I)
to give the title compound (80 g).

with heptane (2x125 ml) to give the title compound (308.0 g
wet weight), which is stored under nitrogen and used directly.

5

Preparation 3 [trans-4-(Methyl {7-[(4-methylphenyl)
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino)
cyclohexyl]methanesulfonic acid

10

1

H-NMR (dcDMSO): 1.17-1.32 (2H), 1.57-1.73 (4H),
1.76-1.92 (lH), 1.93-2.08 (2H), 2.30-2.39 (3H), 2.53-2.62
(3H), 2.87-2.98 (2H), 3.07-3.17 (3H), 4.53-4.75 (lH), 6.816.94 (lH), 7.38-7.47 (2H), 7.56-7.65 (lH), 7.92-8.02 (2H),
8.15-8.27 (lH)
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Preparation 2 [trans-4-(Methyl {7-[(4-methylphenyl)
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino)
cyclohexyl]methanesulfonyl chloride
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To a solution of the compound of Preparation 3 (210.0 g,
0.42 mo!) in dichloromethane (1.2 I) and N,N-dimethylformamide (4.1 ml) is added thionyl chloride (151.0 ml, 2.1
mo!), over 25 min. The reaction mixture is heated at reflux for
18 h and then reduced in volume to 800 ml, via vacuum
distillation. To the mixture, heated at approximately 30° C., is
added ethyl acetate (1.11) over 1 h, followed by heptane (546
ml), added over 20 min at room temperature. The mixture is
cooled to 0° C. and stirred for 1 hand the resulting precipitate
is collected by filtration under nitrogen. The solid is washed
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Method (a) To a mixture of the compound of Preparation 4
(100.0 g wet weight, 23.5 g dry weight, 47.8 mmol) and
formic acid (82.0 g, 68.0 ml, 1.8 mo!) is added hydrogen
peroxide (35 wt.% in water, 21.0 ml, 0.26 mo!) over l0min.
The reaction mixture is stirred at room temperature for 15 h
and then quenched by addition to an aqueous sodium metabisulfate or metabisulfite solution (33 wt. %, 35 ml). To the
mixture is added water (5 ml), 2-propanol (50 ml) and aqueous sodium hydroxide solution (33 wt.%, 161 ml) and the
slurry is stirred at room temperature for 1 h. The solid material
is collected by filtration, washed with water (100 ml) and
dried in vacuo at 60° C. to give the title compound (26.0 g).
1
H-NMR (dcDMSO): 0.98-1.18 (2H), 1.55-1.76 (5H),
1.99-2.13 (2H), 2.29-2.39 (5H), 3.05-3.15 (3H), 4.47-4.76
(lH), 6.77-6.92 (lH), 7.38-7.48 (2H), 7.54-7.62 (lH), 7.918.02 (2H), 8.17-8.25 (lH)

Method (b) To a solution of the compound of Preparation 3
in IPA-water (585 ml each, 1:1, VAT) was added sodium
sulphate and the mixture was heated to 80-90° C. for 24 hours.
After allowing to cool to r.t. the solvent was evaporated up to
50% and the pH of the reaction mixture adjusted in the range
3-4 by addition of acetic acid. Toluene (11) was added and the
mixture evaporated to 80%. Further toluene (1 I) was added
and the mixture refluxed for 4 hours. The toluene was
decanted and the resultant title compound obtained by drying
under vacuum (168 g).

US 8,987,283 B2
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H-NMR (dcDMSO): 0.98-1.18 (2H), 1.55-1.76 (5H),
1.99-2.13 (2H), 2.29-2.39 (5H), 3.05-3.15 (3H), 4.47-4.76
(lH), 6.77-6.92 (lH), 7.38-7.48 (2H), 7.54-7.62 (lH), 7.918.02 (2H), 8.17-8.25 (lH)

(2H), 3.06-3.14 (3H), 4.44-4.76 (lH), 6.76-6.94 (lH), 7.367.49 (2H), 7.56-7.62 (lH), 7.90-8.02 (2H), 8.17-8.26 (lH)

1

Preparation 4 S-{[trans-4-(Methyl {7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl }amino )cyclohexyl]methyl }ethanethioate

Preparation 5 [trans-4-(Methyl {7-[(4-methylphenyl)
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino)
cyclohexyl]methyl 4-methylbenzenesulfonate

10

15

20

25

30

35

40

45

To a solution of the compound of Preparation 6 (42.0 g,
0.16 mo!) in dichloromethane (11) is added triethylamine
(68.3 g, 0.68 mo!) and 4-dimethylaminopyridine (1.0 g, 8.2
mmol), followed by p-toluenesulfonyl chloride (62 g, 0.33
mo!). The reaction mixture is stirred at room temperature for
2 h, before addition of further p-toluenesulfonyl chloride
(45.5 g, 0.24 mo!). After stirring for 18 h, the mixture is
concentrated in vacuo and a portion of the residue (approximately 309 g) is slurried in methanol (758 ml) for 15 min. To
the slurry is added water (600 ml) and saturated aqueous
sodium hydrogen carbonate solution (142 ml) and the mixture is stirred for 1 h. The solid material is collected by
filtration and washed withmethanol:water [1: 1, 50 ml], water
(50 ml) andhexanes (50 ml). The solid is dried in vacuo at 60°
C. to give the title compound (87.1 g).
1
H-NMR (dcDMSO): 1.02-1.20 (2H), 1.53-1.75 (7H),
2.31-2.39 (3H), 2.39-2.47 (3H), 3.04-3.12 (3H), 3.80-3.91
(2H), 4.34-4.76 (lH), 6.78-6.93 (lH), 7.37-7.54 (4H), 7.547.64 (lH), 7.75-7.84 (2H), 7.91-8.01 (2H), 8.14-8.25 (lH)

50

Preparation 6 {trans-4-[Methyl(7H-pyrrolo[2,3-d]
pyrimidin-4-yl)amino]cyclohexyl}-methanol

55

To a solution of potassium thioacetate (11.4 g, 99.4 mmol)
in dimethyl sulfoxide (30 ml) is added the compound of
Preparation 5 (50.0 g, 87 .9 mmol) in dimethyl sulfoxide (130
ml). The reaction mixture is heated at 55° C. for 3 h, cooled to
room temperature and quenched by addition to an aqueous
sodium hydrogen carbonate solution (0.lM, 640 ml). The
mixture is cooled to 13° C. and the resulting precipitate is
collected by filtration and washed with water (250 ml) to give
the title compound (204.0 g wet weight).
1

H-NMR (dcDMSO): 1.06-1.23 (2H), 1.39-1.51 (lH),
1.51-1.70 (4H), 1.74-1.88 (2H), 2.30-2.40 (6H), 2.73-2.84

60
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A mixture of the compound oftrans-4-(Methylamino)cyclohexyl]methanol (may be prepared according to the proce-
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dure described in WO 2002/14267)(50.0 g, 0.35 mo!),
4-chloro-7H-pyrrolo[2,3-d]pyrimidine (commercially available, 42.9 g, 0.27 mo!) and potassium carbonate (57 .3 g, 0.42
mo!) in water (1 I) and 1,4-dioxane (100 ml) is heated at 90°
C. for 15 h. To the mixture is added the compound of Preparation 7 (2.0 g, 14.0 mmol) and the reaction mixture is heated
at 90° C. for a further 1 h. After cooling to room temperature,
the mixture is stirred for 1 hand the solid material is collected
by filtration, washed with water (150 ml) and dried in vacuo
at 65° C. to give the title compound (72.7 g).

1

H-NMR (dcDMSO):
Preparation 8
[trans-4-(Methy!amino )cyclohexy!]methanol

5

10

1

H-NMR (dcDMSO): 1.00-1.19 (2H), 1.30-1.45 (lH),
1.52-1.77 (4H), 1.77-1.91 (2H), 3.09-3.20 (3H), 3.20-3.29
(2H), 4.37-4.51 (lH), 6.45-6.57 (lH), 7.06-7.17 (lH), 8.018.14 (lH)

15

Preparation 7 [trans-4-(Methyl {7-[(4-methylphenyl)
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino)
cyclohexyl]methanesulfinate

20

25

30

Vitride solution (65%, 7 67 ml, 2.465 mo!) was added dropwise over 1 h to a solution oftrans-4-[(tert-butoxycarbonyl)
amino ]cyclohexanecarboxylic acid (commercially available,
100 g, 0.4109 mo!) in toluene (1 I). After the addition was
complete the reaction mixture was heated to reflux for 1001100 C. The reaction mixture was quenched withaq. Sodium
sulphate solution (800 ml) at temperatures below 10° C. The
reaction mixture was filtered through celite and the filter cake
washed with DCM (500 ml) followed by water (100 ml). The
organics layer was separated and the aqueous layer extracted
twice with DCM (600 ml then 400 ml). The combined organics layers were dried over sodium sulphate and concentrated
in vacuo to give the title compound (62 g).
1
H-NMR(CD 3 OD): 1.08-1.31 (4H), 1.51-1.64(1H), 1.932.05 (2H), 2.10-2.22 (2H), 2.38-2.50 (lH), 2.50-2.54 (3H),
3.48-3.55 (2H)

35

Example la

40

Preparation of N-methyl-1-{ trans-4-[ methyl(7Hpyrrolo[2,3-d]pyrimidin-4-yl)amino]
cyclohexyl} methanesulfonamide

45

50

To a solution of the compound of Preparation 4 (60.0 g,
0.418 mo!) in acetone (600 ml) is added triethylamine (117.5
ml, 0.837 mo!) and catalytic potassium iodide (3.4 g, 0.05
mo!), followed by 4-chloro-7H-pyrrolo[2,3-d]pyrimidine
(commercially available, 102.8 g, 0.335 mo!). The resulting
mixture was heated to 60° C. for 22 h. After allowing to cool
to r.t. acetone (300 ml) was added, followed by triethylamine
(146.9 ml, 1.04 mo!) then mesyl chloride (81.7 ml, 1.047
mo!). After stirring for 4 hours at r.t. water was added (1.81)
whereupon the product precipitated out. The product was
filtered, dried and triturated with a mixture ofMTBE-heptane
(6:4, 600 ml). A second trituration from MTBE-heptane was
conducted and the resultant title compound obtained ( 120 g).

55

60

65

To a solution of the compound of Preparation 1 (250.0 g,
0.48 mo!) in 2-propanol (1.2 I) is added lithium hydroxide
(48.7 g, 2.03 mo!) in water (1.2 I). The reaction mixture is
heated at 40° C. for 8 h and then stirred at room temperature
for 18 h. The mixture is filtered, washing through with 2-propanol:water (1: 1, 100 ml) and the filtrate is adjusted to pH 7.5
by addition of hydrochloric acid (6N). After stirring for 1 h,
the solid material is collected by filtration, washed with
2-propanol:water (1 :2, 240 ml) and dried in vacuo at 60° C. to
give the title compound (148.7 g) as a free base (Example la).
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H-NMR (dcDMSO): 1.20-1.39 (2H), 1.62-1.75 (4H),
1.77-1.91 (lH), 1.97-2.11 (2H), 2.54-2.63 (3H), 2.89-2.99
(2H), 3.10-3.21 (3H), 4.44-4.86 (lH), 6.43-6.61 (lH), 7.017.19 (lH), 7.94-8.16 (lH)

TABLE I-continued

1

Powder X-ray Diffraction Peaks expressed in
degrees 2-theta, ±0.2 degrees, approximately

Example lb
Preparation ofN-methyl-1-{ trans-4-[methyl(7Hpyrrolo[2,3-d]pyrimidin-4-y!)amino]
cyclohexy} methanesulfonamide maleic acid salt
A mixture of the compoundofExample la (212.0 g, 628.3
mmol) and maleic acid (67.2 g, 579.0 mmol) in 1-butanol
(3200 ml) and water (400 ml) is stirred at room temperature
for 18 h. The mixture is reduced in volume to 1600 ml, via
vacuum distillation (55° C., 100 mbar) and then cooled to 0°
C. The resulting solid is collected by filtration, washed with
heptane (500 ml) and dried in vacuo at 35° C. to give the
maleate salt of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,
3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide (253.0 g) as a crystalline
form known as Form A.
Experimental MH+ 338.2; expected 338.2.
1
H-NMR (dcDMSO): 1.24-1.38 (2H), 1.68-1.92 (5H),
2.00-2.11 (2H), 2.56-2.61 (3H), 2.91-3.00 (2H), 3.15-3.27
(3H), 4.39-4.70 (lH), 6.53-6.73 (lH), 7.16-7.36 (lH), 8.078.29 (lH).

Angle

Intensity

2-theta

I%

20.659

27.8

21.583

11.1

22.642

12.7

23.08

12.1

24.86

19.8

25.602

10.7

10

15

20

26.582

13

27.02

30.6

27.721

18.7

28.161

23.7

28.38

28.9

25

TABLE2
Example le

30
Selected Powder X-ray Diffraction Peaks expressed

Method for collecting powder X-ray diffraction for
N-methyl-1-{ trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino ]cyclohexyl }-methanesulfonamide
maleic acid salt (Form A)
The powder X-ray diffraction patterns for Form A, N-methyl-1-{ trans-4-[ methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)
amino ]cyclohexyl}-methanesulfonamide maleic acid salt
were collected using a Bruker-AXS Ltd. D4 powder X-ray
diffractometer fitted with an automatic sample changer, a
theta-theta goniometer, automatic beam divergence slit, and a
PSD Vantec-1 detector. The sample was prepared for analysis
by mounting on a low background cavity silicon wafer specimen mount. The specimen was rotated whilst being irradiated
with copper K-alpha 1 X-rays (wavelength=l.5406 Angstroms) with the X-ray tube operated at 40 kV/35 mA. The
analyses were performed with the goniometer running in
continuous mode set for a 0.2 second count per 0.018° step
over a two theta range of 2° to 55°. The results are summarized in Table 1 and Table 2.

in degrees 2-theta, ±0.2 degrees, approximately

35

40

Angle
2-theta

Intensity
I%

6.178
8.519
12.601
13.819
15.478
15.719
16.32
17.997
18.539
20.298

72.6
24.5
88.4
38
34.3
100
27.1
32.3
44.5
18.2

Lattice Dimension

Intensity

d(A)

I%

6.179

14.3

73

12.601

7.01

88

15.719

5.63

100

18.539

4.78

45

27.02

3.29

30.6

28.38

3.14

28.9

45

50

TABLE 1
Powder X-ray Diffraction Peaks expressed in
degrees 2-theta, +0.2 degrees, approximately

Angle
2-theta

55

As is readily apparent to one skilled in the art, the results of
any X-ray powder diffraction may vary and subsequent
XRPD's will not be identical, even when carried out on the
same lot of material. This variance can be due to test sample
preparation, temperature, the particular model of X-ray diffractometer used, the operator's technique, etc. The term
"approximately" if used in defining a peak in an X-ray powder diffraction pattern is defined as the stated 20
value±0.2°28. Any determination of whether a crystalline
form is the Form A polymorph and encompassed by the
claims should be interpreted in light of the variability in this
test.

60

65

This variability is demonstrated in FIG. 1. The two different lots of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]
pyrimidin-4-y!)amino ]cyclohexyI}-methanesulfonamide
maleic acid salt Form A were submitted to the same XRPD
diffractometer. The characteristic peaks in FIG. 1 confirming
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that it is the Form A polymorph. However, the relative intensity of these peaks as well as the other identifying peaks
varied slightly.

chased from (Invitrogen Corporation, Madison, Wis.).
Recombinant JAK-1 (GST-JAK-1 (852-1142)) and Tyk-2
(GST-Tyk2 (870-1187, C1187S)) used in this study were
expressed and purified at Pfizer Laboratories. Adenosine
5'-triphosphate (ATP) was obtained from Sigma Chemical
Company, St. Louis, Mo. The JAKtide peptide (peptide
sequence, FITC-KGGEEEEYFELVKK (SEQ ID NO:1))
used for the JAK-2 and JAK-3 assays and the IRS-1 peptide
(peptide sequence, 5-FAM-KKSRGDYMTMQIG (SEQ ID
NO:2)) used for the JAK-1 and Tyk-2 assays were purchased
from (American Peptide Company, Sunnyvale, Calif.). Coating Reagent 3 was purchased from (Caliper Life Sciences,
Hopkinton, Mass.).
Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or
the IRS-1 peptide (JAK-1 and Tyk-2). Reactions were carried
out in a 384-well plate (Matrical MP-101) in a 10 microliter
total volume. Reaction mixtures contained 20 mM HEPES,
pH 7.4, 10 mM magnesium chloride, 0.01 % bovine serum
albumin (BSA), 0.0005% Tween-20, ATP (4 micromolar for
JAK-2 andJAK-3, 40micromolarfor JAK-1 and 7 micromolar for Tyk-2)), 2% DMSO and 1 micromolar peptide substrate (JAKtide for JAK-2 and JAK-3 or IRS-1 peptide for
JAK-1 and Tyk-2). Compounds were diluted serially in 100%
dimethyl sulfoxide and tested in an 11 point dose response in
duplicate or quadruplicate (200 nl of compound/DMSO was
added per 10 microliterreaction). The reactions were initiated
by the addition of enzyme to the final concentration of 2 nM
JAK-2, 1 nM JAK-3, 7 nM Tyk2 or 20 nM JAK-1. The assay
was run for 240 minutes for JAK-1, 150 minutes for JAK-2,
90 minutes for JAK-3 and 60 minutes for Tyk-2. The assays
were stopped at the specified times with 20 microliter of 140
mM HEPES, 22.5 mM EDTA and 0.15% Coating Reagent 3.
The plates were placed on a LabChip 3000 (LC3000) instrument (Caliper Life Sciences) to measure the formation of
phosphorylated peptide. Data was analyzed using Hits Well
Analyzer Software from (Caliper Life Sciences) to obtain the
amount of product formed.
Data was then imported into an internal application where
each data point was expressed as% inhibition based on uninhibited and no enzyme controls. Dose-response data was then
fit using a 4 parameter logistic equation (Equation 1) to determine an IC 50 value.

Example 2

5

Preparation of N-cyclobutyl-1-{ trans-4-[ methyl(7Hpyrrolo[2,3-d]pyrimidin-4-y!)amino]
cyclohexyl} methanesulfonamide
10

15

20

Following the general procedure of Example 1 and making
non-critical variations but substituting the precursor to
cyclobutanamine, the title compound is provided.
Experimental MH+ 378.0; expected 378.2
1
H-NMR (dcDMSO): 1.22-1.32 (2H), 1.47-1.70 (6H),
1.78-2.04 (5H), 2.16-2.24 (2H), 2.85-2.86 (2H), 3.15 (3H).
3.68-3.78 (lH), 4.60-4.72 (lH), 6.51-6.54 (lH), 7.11-7.12
(lH), 7.44-7.49 (lH), 8.08 (lH), 11.60 (lH)

25

30

Example 3
35

Preparation ofN-ethyl-1-{ trans-4-[ methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]
cyclohexyl} methanesulfonamide
40

max-min
y=

45

50

Following the general procedure of Example 1 and making
non-critical variations but substituting the precursor to ethanamine, the title compound is provided.
Experimental MH+ 352.0; expected 352.2
1
H-NMR (CDCl 3 ): 1.24-1.44 (5H), 1.64-1.74 (2H), 1.872.09 (3H), 2.15-2.21 (2H), 2.97-2.99 (2H), 3.18-3.27 (5H),
4.46-4.52 (lH), 4.74-4.86 (lH), 6.55 (lH), 7.04 (lH), 8.28
(lH)

Equation 1

(x)s+min

1+/Cso

Where max is the fitted uninhibited value, min is the fitted
complete inhibition value, and s is the slope factor.
Using this protocol, the following results were generated
for the title compounds of Example 1 and 2.
TABLE3
JAK Enzymatic Assay Result

55

Ex.#

JAK-1 ICso

la

9.53 nM
45.0 nM

2

JAK-2 ICso
17.5 nM
101.0 nM

JAK-3 IC 50

Tyk-2 IC 50

95.1 nM
742 nM

75.1 nM

60

Example 4

Example 5

JAK Enzymatic Assay

Canine in vitro T-cell Proliferation Assay
65

Materials: Recombinant JAK-2 (Catalog Number
PV4210) and JAK-3 (Catalog Number PV3855) were pur-

T-cell activation plays a key role in a variety of inflammatory and autoimmune disorders as well as asthma, allergies
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and pruritus. Since T-cell activation can, in part, can be trigand proinflammatory cytokine receptors could be effective in
gered by cytokines that signal through the JAK-STAT pathinhibiting, reducing or minimizing flea-associated pruritus
way, a JAK inhibitor could be effective against such diseases
and dermatitis.
involving aberrant T-cell activation.
Study Design
Methods: Canine whole blood was collected in sodium 5
Twenty eight male and female dogs of mixed breeds rangheparin tubes from 29 beagle dogs and 23 mixed breed dogs.
ing in weight from 5-35 kg and greater than one year of age
Whole blood (20 µL) was plated in 96-well plates (Costar
were infested with approximately 100 unfed adult cat fleas
3598) with 180 µL of medium (RPMI 1640, Gibco #21870(Ctenocephalides felis) 14 days prior to the start of dosing and
076, with 1% heat inactivated fetal bovine serum, Gibco
10 reinfested with 30 fleas per dog every 4 days throughout the
#10082-39, 292 µg/ml L-glutamine, Gibco #250030-081,
study. Seven days before dosing, twenty four dogs were ran100 u/ml penicillin and 100 µg streptomycin per ml, Gibco
domized
into three different treatment groups, placebo, 0.5
#15140-122) containing vehicle control or test compound
mg/kg
or
0.25 mg/kg of the compound of Example 1b, based
(0.001 to 10 µM), concanavalin A (ConA; 1 µg/ml, Sigma
C5275), and canine interleukin-2 (IL-2; 50 ng/ml, R&D Sys- 15 on visual analog scale (VAS) scores for skin lesions. Treatments were given orally twice a day for 28 days, and pruritic
tems 1815-CL/CF). Wells containing whole blood, medium
behavior as well as erythema and skin lesions were was
with vehicle control and no ConA or IL-2 were used as
assessed during the study. Pruritic behavior was recorded by
background controls. Plates were incubated at 37° C. for 48
placing dogs into pens with video recording capability, and
hours. Tritiated thymidine, 0.4 µCi/well (Perkin Elmer,
20 recording their activity over 4 hours. Pruritic activity was
Net027A-005MC), was added for 20 additional hours. Plates
quantitated by determining how many seconds the dogs spent
were frozen and then thawed, washed and filtered using a
scratching. Skin lesions were recorded by image capture of
Brandel MLR-96 cell harvester and prewet filter mats (Wallac
abdominal, inguinal region and the severity ranked according
1205-401, Perkin Elmer). Filters were dried at 60° C. for one
hour (Precision 16EG convection oven) and placed into filter 25 to a visual analog scale (VAS).
Statistical Analysis:
sample bags (Wallac 1205-411, PerkinElmer) with l0mL of
Video
captured elapsed time of pruritic behavior was anascintillant (Wallac 1205-440, Perkin Elmer). Sealed filters
lyzed using a mixed linear model for repeated measures. The
were counted on a LKB Wallac 1205 Betaplate liquid scinmodel included fixed effects of treatment and day of study
tillation counter. Data were collected via Gterm Betaplate
30 and the interaction of treatment and day of study. Random
program vl .1 (Wallac copyright 1989-1990) and transformed
effects included block, the interaction of block and treatment
into percent inhibition, calculated using the following forand error. Baseline data for pruritic behavior (day -1) were
mula:
used as covariate in the analysis of pruritic behavior. Least
squares means were used as estimates of treatment means.
35
Standard errors of least squares means were estimated and
(Mean Drug Treatment cpm - Mean ECK cpm)
100- - - - - - - - - - - - - - - - - x 100 =
[ (Mean Non-Drug Treatment cpm - Mean ECK cpm)
90% confidence intervals were constructed. Geometric
means
were computed from the least squares means for log% Inhibition
transformed data. A priori contrasts were used to assess treat40 ment. Treatment differences were assessed at the 10% level of
Data were graphically displayed as percent inhibition using
significance (Ps0.10).
GraphPad Prism 4.0, and IC 50 curves were fitted using a point
Results
to point analysis.
The treatment results are shown in FIG. 2 and FIG. 3.
Results The average IC 50 values obtained when using
Lesions and erythema were significantly reduced in the 0.5
whole blood from beagles was 66.3 nM for the compound of 45 mg/kg group. FIG. 2 illustrates Day 27 VAS Scores for
Example la; 410nM for Example 2; and 83 nM for Example
Example 1b in flea allergic dogs (Least Squares Means).
3. The average IC 50 value obtained when using whole blood
Significant reductions in pruritus as compared to placebo at a
from mixed breed dogs was 138 nM for the compound of
10% level of significance were seen at various time points
Example la. These data suggest that the compounds of the 50 during the study for both groups (days 1, 4 and 12 for the 0.25
present invention are effective in inhibiting T-cell proliferamg/kg dose and on days 1 and 20 for the 0.5 mg/kg dose).
tion, a key feature in many diseases.
FIG. 3 illustrates Seconds of Pruritus per 4 hour recording for
example lb in flea allergic dogs (Long Geometric Mean).
Example 6

l

55

Reducing Flea-associated Pruritus and Dermatitis Assay
Flea-associated pruritus and dermatitis are common skin conditions in dogs. Pruritus is one of the most severe clinical
signs associated with flea associated dermatitis, and continued scratching, face rubbing, and foot chewing can lead to a
variety of changes to the skin such as erythema, edema,
alopecia, lichenification, and hyper pigmentation. Flea-associated pruritus and dermatitis can be induced experimentally.
In these models, inflammatory cells and cytokines have been
shown to mediate immune reactions to allergens. Therefore, a
JAK inhibitor that inhibits signal transduction of pruritogenic

Example 7
Cell Proliferation Inhibitory Assay
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Feline Cell Lines The MYA-1 and FETJ are feline T-lymphoblast cell lines obtained from ATCC (Manassas, Va.).
These cells were cultured in RPMI 1640 complete media
supplemented with 10% FBS at 37° C. in a humidified incubator with 5% CO 2 .
Ex Vivo Canine Lymphoma Nodal Tissue
Malignant lymph nodes were excised by veterinary staff at
Michigan State University (MSU) Veterinary College, placed
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into transport media (Advanced RPMI 1640 complete
medium supplemented with 10% Fetal Bovine Serum (FBS),
100 U/mL penicillin, 100 ug/mL streptomycin and 0.25
ug/mL Amphotercin B (Invitrogen/Gibco®). Nodes were
processed within 24 hours of removal by mincing into tiny
pieces and passing through a tissue sieve. Cell suspensions
were spun at 200xg, supernatant was removed, and the cell
pellet was resuspended in NH4 Cl for 10 minutes at room
temperature. The cell suspension was pelleted by centrifugation; the NH4 Cl was removed and washed once with Hanks
Balanced Salt Solution (HBSS), followed by re-suspension in
Proliferation Medium (Advanced RPMI complete, 1% FBS,
50 nM 2-Mercaptoethanol, 100 U/mL penicillin, 100 ug/mL
streptomycin and 0.25 ug/mL Amphotercin B). The cell suspension was then passed through a 100 µm ny Ion cell strainer
(BD-Falcon) and counted using a hemacytometer. Cells were
cultured in either Proliferation Medium alone, Proliferation
Medium supplemented with 0.005% Pansorbin® (Heat inactivated, formalin-fixed Staphylococcus Aureus cells (SAC),
Calbiochem), and 10 ng/mL canine IL-2 (R&D Systems), or
Proliferation Medium supplemented with 125 ng/mL concavalinA (Sigma) and 125 ng/mL lipopolysaccamide (LPS;
Calbiochem).
In Vitro Anti-Proliferation Assay Method
Cells cultured in medium described above were plated in
96-well Costar plates (Corning) at a density of lxl0 3 cells/
well (feline cell lines) or 2xl 0 5 cells/well (lymph node cells)
and exposed to various concentrations oftest compounds for
up to 5 days at 3 7° C. in a humidified incubator with 5% CO 2 .
Effects on proliferation were determined using the CellTiter
96® AQueous Non-Radioactive Cell Proliferation Assay
(Promega) according to manufacturer's instructions. In general, proliferation was indirectly measured using a soluble
tetrazolium salt (MTS) and an electron coupling agent. MTS
bioreduction into a formazan product soluble in tissue culture
medium was monitored by absorbance at 490 nM on a Spectramax plate reader using Softmax Pro 4. 6 software (Molecu-

lar Devices). Data were graphically displayed as percent
DMSO control using GraphPad Prism 4.00, and IC 50 curves
were fitted using a non-linear regression model with a sigmoidal dose response.
5

Results
10

15

Table 4 demonstrates that the compound of Example 1 can
inhibit proliferation of the feline lymphoid cell line MYA-1
that is dependent on IL-2 for proliferation, but not an IL-2
independent line (FETJ). The compound of formula IA or its
salt can also inhibit proliferation of canine nodal tissue
obtained from dogs diagnoses with T- or B-cell lymphoma.
These results suggest a JAK inhibitor may be effective in
treating canine and feline lymphomas.
TABLE4
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Cell Line or

Stimulant in

Species

Lymph Node Description

Culture Medium

Feline
Feline

MYA-1

25 Canine
Canine
Canine

357

MSULN8

SAC+ IL-2

38

MSULN9

lymphoma
De nova B-cell

LPS + ConA

147

MSULN9

lymphoma
De nova B-cell

SAC+ IL-2

100

LPS + ConA

687

LPS + ConA

64

Canine

MSULN 10

Canine

MSULN 11
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<160> NUMBER OF SEQ ID NOS, 2
SEQ ID NO 1
LENGTH, 14
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, JAKtide peptide

<400> SEQUENCE, 1
Lys Gly Gly Glu Glu Glu Glu Tyr Phe Glu Leu Val Lys Lys
1
5
10

<210>
<211>
<212>
<213>
<220>
<223>

LPS + ConA

lymphoma
De nova T-cell

122 (n - 2)
>1000

lymphoma

SEQUENCE LISTING

<210>
<211>
<212>
<213>
<220>
<223>

MSULN8

Lymphoid line
Lymphoid line
De nova T-cell

FETj

30
Canine

IC50 (nM)

SEQ ID NO 2
LENGTH, 13
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, IRS-1 peptide

<400> SEQUENCE, 2
Lys Lys Ser Arg Gly Asp Tyr Met Thr Met Gln Ile Gly
1
5
10

Chemotherapy
resistant B-cell
lymphomaDe nova B-cell
lymphoma

US 8,987,283 B2
29

30

What is claimed is:
1. A method for treating allergic reactions, allergic dermatitis, atopic dermatitis, eczema, or pruritus in a mammal comprising administering to a mammal in need a therapeutically
effective amount of a compound of formula I:

2. The method of claim 1 wherein the therapeutically effective amount is from 0.01 mg/kg of body weight/day to 100
mg/kg of body weight/day.
3. The method of claim 1 wherein the therapeutically effective amount is from 0.1 mg/kg of body weight/day to 10
mg/kg of body weight/day.
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4. The method of claim 1 wherein the manmial comprises
companion animals.

0

N

5. The method of claim 4 wherein the companion animals
are dogs.

N::::::"'

l

'\

I
N

15

I
H

or a pharmaceutically acceptable salt thereof wherein R 1 is
C 1 _4 alkyl optionally substituted with hydroxy.
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6. The method of claim 1 wherein the manmial comprises
livestock.
7. The method of claim 1 wherein the compound of formula
I is adminiS tered orally, parenterally, or topically.

* * * * *

